MedTrace Logo

Phase I Study to Assess Absorption, Metabolism & Excretion of a Single Oral Dose [14C]AZD0530 in Healthy Male Volunteers

NCT00853983 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2009-05-21

No results posted yet for this study

Summary

The aim of this study is to show how the body absorbs, metabolises and excretes the drug \[14C\]AZD0530. As for all clinical trials, safety and tolerability of the drug will be evaluated.

Conditions

  • Healthy

Interventions

DRUG

[14C] AZD0530

Solution, Oral, once

Sponsors & Collaborators

Principal Investigators

  • Raj Chetty, MD · AstraZeneca, Clinical Pharamcology Unit, Alderley Park

  • Mary Stuart, MD · AstraZeneca, Parklands, Alderley Park

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-31
Completion
2009-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00853983 on ClinicalTrials.gov